February 20, 2008 – ConjuChem Biotechnologies Inc. (TSX:CJB) announced that dosing has been initiated in its Phase II clinical study for the treatment of Type 2 diabetes using the Company’s proprietary PC-DAC™:Exendin-4 compound. The study is the first of two Phase II studies that the Company plans to conduct concurrently... [PDF] ConjuChem's Press Release- PDF Communiqué de Presse ConjuChem-
Tuesday, February 26, 2008
ConjuChem, Phase II Study of PC-DACTM:Exendin-4
February 20, 2008 – ConjuChem Biotechnologies Inc. (TSX:CJB) announced that dosing has been initiated in its Phase II clinical study for the treatment of Type 2 diabetes using the Company’s proprietary PC-DAC™:Exendin-4 compound. The study is the first of two Phase II studies that the Company plans to conduct concurrently... [PDF] ConjuChem's Press Release- PDF Communiqué de Presse ConjuChem-
